A
Advance Medical Devices
The John P. and Kathrine G. McGovern Medical School, located in the Texas Medical Center in Houston, Texas, is the graduate medical school associated with the University of Texas Health Science Center at Houston (UTHealth). Established by the Texas Legislature in 1969 as the University of Texas Medical School at Houston, the McGovern Medical School enrolled its first class of 19 students in 1970. Today, the school annually enrolls a class size of 240 students, making it the seventh-largest medical school in the United States.
Country/Area ：India
Industry ：Hospitals & ClinicsHealthcare
Company address ：6431 Fannin St Rm G300, Houston, Texas, 77030, United States
Company website ：*****
Company phone ：(713) 500-5116
Established ：2006
Company Revenue ：$34,694,000
Number of employees ：66
SIC Code ：80801
NAICS Code ：62621
Company News
UTHealth Houston announces new dean, other leadership changes at McGovern Medical School
Jul 29, 2022
A new executive dean is taking over at UTHealth Houston’s McGovern Medical School, the...
Jul 29, 2022
Business Info
CIN ：U33120MH2006PTC159164
Registered State ：Maharashtra
Registrar Of Companies ：RoC-Mumbai
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Private
Company Status ：Strike Off
Registered Office Address ：52 ASIATIC ARCADE VARTAKNAGAR,POKHRAN RD NO.1 THANE WEST THANE MH IN 000000
Authorized Cap ：500000.00
Paidup Capital ：500000.00
Web Summary
Q1: What is the name of the company mentioned in the text?
A1: The company mentioned in the text is Advance Medical Devices.
Q2: Is Advance Medical Devices a medical device company?
A2: Although the text does not explicitly state that Advance Medical Devices is a medical device company, it appears to be related to healthcare and research, as indicated by the mention of clinical trials and neurologic conditions.
Q3: What type of grant was used to fund the project at McGovern Medical School?
A3: The project at McGovern Medical School was funded with a $2.9 million grant from the National Institutes of Health (NIH).
Q4: Who is leading the project funded by the NIH?
A4: Anjail Z. Sharrief, MD, MPH, is the principal investigator for the trial and professor with the Department of Neurology at McGovern Medical School.
Q5: What are some potential barriers to participation in clinical trials that the project aims to address?
A5: The project aims to address barriers such as requiring patients to come into the clinic during the workweek instead of Saturdays, followup televisits instead of inperson visits, and limited funding for transportation and bilingual research staff.
Q6: What is the goal of the Brain Health Equity Collaborative established by the project?
A6: The Brain Health Equity Collaborative aims to facilitate academic and community partnerships for clinical trial development, with a focus on including the voice of underserved communities in the design of clinical trials.
Q7: How does the project aim to improve neurological outcomes for underserved populations?
A7: The project aims to improve neurological outcomes for underserved populations by building an infrastructure for communityengaged research interventions that are more inclusive and applicable to a broader range of patients affected by neurologic conditions.
Q8: What is the expected outcome of the project in terms of its impact on clinical trials?
A8: The project aims to make clinical trials more likely to include a broader patient population, with research findings and outcomes being more applicable to the wider range of patients affected by neurologic conditions.
A1: The company mentioned in the text is Advance Medical Devices.
Q2: Is Advance Medical Devices a medical device company?
A2: Although the text does not explicitly state that Advance Medical Devices is a medical device company, it appears to be related to healthcare and research, as indicated by the mention of clinical trials and neurologic conditions.
Q3: What type of grant was used to fund the project at McGovern Medical School?
A3: The project at McGovern Medical School was funded with a $2.9 million grant from the National Institutes of Health (NIH).
Q4: Who is leading the project funded by the NIH?
A4: Anjail Z. Sharrief, MD, MPH, is the principal investigator for the trial and professor with the Department of Neurology at McGovern Medical School.
Q5: What are some potential barriers to participation in clinical trials that the project aims to address?
A5: The project aims to address barriers such as requiring patients to come into the clinic during the workweek instead of Saturdays, followup televisits instead of inperson visits, and limited funding for transportation and bilingual research staff.
Q6: What is the goal of the Brain Health Equity Collaborative established by the project?
A6: The Brain Health Equity Collaborative aims to facilitate academic and community partnerships for clinical trial development, with a focus on including the voice of underserved communities in the design of clinical trials.
Q7: How does the project aim to improve neurological outcomes for underserved populations?
A7: The project aims to improve neurological outcomes for underserved populations by building an infrastructure for communityengaged research interventions that are more inclusive and applicable to a broader range of patients affected by neurologic conditions.
Q8: What is the expected outcome of the project in terms of its impact on clinical trials?
A8: The project aims to make clinical trials more likely to include a broader patient population, with research findings and outcomes being more applicable to the wider range of patients affected by neurologic conditions.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
